Advertisement
Vicore Pharma Holding AB (publ) (6Y4.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Follow
At close: 08:07AM CEST
| Previous Close | 0.7530 |
| Open | 0.7040 |
| Bid | 0.7450 x N/A |
| Ask | 0.7730 x N/A |
| Day's Range | 0.7040 - 0.7040 |
| 52 Week Range | 0.5590 - 2.0050 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 157.647M |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings Date | Nov 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Increase of Number of Shares and Votes in Vicore Pharma
STOCKHOLM, SE / ACCESSWIRE / May 31, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 31, 2024 - Vicore Pharma Holding AB (STO: VICO) ("Vicore") announced today that the number of Vicore shares and votes has increased following the exercise ...
- ACCESSWIRE
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis
STOCKHOLM, SWEDEN / ACCESSWIRE / May 20, 2024 / Vicore Pharma Holding (STO:VICO) Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment. The therapy was safe and well tolerated with no treatment-related ...
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.